Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, multiple-dose, placebo-controlled Phase II clinical study of EVT201 for the treatment of insomnia

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, multiple-dose, placebo-controlled Phase II clinical study of EVT201 for the treatment of insomnia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimdazenil (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Zhejiang Jingxin Pharmaceutical

    • Most Recent Events

    • 08 Feb 2024 Results assessing efficacy and safety of Dimdazenil on sleep variables in patients with insomnia disorder, published in the Sleep.
    • 05 Dec 2023 Primary endpoint has been met (Total sleep time (TST) monitored by PSG during the double-blind treatment period (Nights 1/2 and 13/14 of the double-blind treatment period ; Effectiveness index + safety index)) , according to Results published by Oxford University Press on behalf of Sleep Research Society
    • 05 Dec 2023 According to Results published by Oxford University Press on behalf of Sleep Research Society, Zhao Zhongxin, Master of Medicine, chief physician, Shanghai Changzheng Hospital is the principal investigator of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top